|
|
 Previous Article | Table of Contents | Next Article 
Prognostic Value of Numerical Chromosome Aberrations in Multiple
Myeloma: A FISH Analysis of 15 Different Chromosomes
J.A. Pérez-Simón,
R. García-Sanz,
M.D. Tabernero,
J. Almeida,
M. González,
J. Fernández-Calvo,
M.J. Moro,
J.M. Hernández,
J.F. San Miguel, and
A. Orfão
From the Castellano-Leonés (Spain) Cooperative Group for the
Study of Monoclonal Gammopathies, Department of Hematology, University
Hospital of Salamanca, University of Salamanca; and the General Service
of Cytometry, University of Salamanca, Salamanca, Spain.
Recent observations indicate that chromosome aberrations are
important prognostic factors in patients with multiple myeloma (MM)
treated with high-dose chemotherapy. Nevertheless, the inherent problems of conventional cytogenetics have hampered the systematic evaluation of this parameter in series of patients treated with conventional chemotherapy. Fluorescence in situ hybridization (FISH)
analysis is an attractive alternative for evaluation of numerical
chromosomal changes. In the present study, we analyze the relationship
between aneuploidies of 15 different chromosomes assessed by FISH and
prognosis in a series of 63 patients with MM treated with conventional
chemotherapy. After a median follow-up of 61 months (range, 6 to 109),
49% of patients are still alive with a median survival of 33 months.
The overall incidence of numerical chromosome abnormalities was 70%.
This incidence significantly increased when seven or more chromosomes
were analyzed (53 patients), reaching 81%. Trisomies of chromosomes 6, 9, and 17 were associated with prolonged survival
(P = .033, P = .035, and P = .026,
respectively); by contrast, overall survival (OS) was
lower in cases with monosomy 13 (as assessed by deletion of Rb gene,
P = .0012). From the clinical point of view, loss of Rb
gene was associated with a poor performance status; low hemoglobin
levels; high creatinine, C-reactive protein, and lactic dehydrogenase
serum levels; high percentage of bone marrow plasma cells
(BMPC); extensive bone lytic lesions; and advanced clinical stage.
Other chromosome abnormalities such as trisomy of chromosome 9 and 17 were associated with good prognostic features including high hemoglobin
levels, early clinical stage,  2microglobulin less than 6 µg/mL, and low percentage of BMPC. A multivariate analysis for OS
showed that S-phase PC greater than 3% (P = .010) and
2microglobulin serum levels greater than 6 µg/mL
(P = .024), together with monosomy of chromosome 13 (P = .031) and nontrisomy of chromosome 6 (P = .048) was the best combination of independent
parameters for predicting survival in patients with MM. According to
these results, chromosomal analysis is of great use in patients with MM
at diagnosis to have a correct prognostic evaluation for clinical
decision making.
Blood, Vol. 91 No. 9 (May 1), 1998:
pp. 3366-3371
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Hanlon, L. W. Harries, S. Ellard, and C. E. Rudin
Evaluation of 13q14 Status in Multiple Myeloma by Digital Single Nucleotide Polymorphism Technology
J. Mol. Diagn.,
September 1, 2009;
11(5):
450 - 457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Khong, J. Sharkey, and A. Spencer
The effect of azacitidine on interleukin-6 signaling and nuclear factor-{kappa}B activation and its in vitro and in vivo activity against multiple myeloma
Haematologica,
June 1, 2008;
93(6):
860 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Blood,
October 1, 2006;
108(7):
2165 - 2172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Stewart and R. Fonseca
Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling
J. Clin. Oncol.,
September 10, 2005;
23(26):
6339 - 6344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Gutierrez, J. L. Garcia, J. M. Hernandez, E. Lumbreras, M. Castellanos, A. Rasillo, G. Mateo, J. M. Hernandez, S. Perez, A. Orfao, et al.
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma
Blood,
November 1, 2004;
104(9):
2661 - 2666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Specht, E. Haralambieva, K. Bink, M. Kremer, S. Mandl-Weber, I. Koch, R. Tomer, H. Hofler, E. Schuuring, P. M. Kluin, et al.
Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels
Blood,
August 15, 2004;
104(4):
1120 - 1126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kroger, G. Schilling, H. Einsele, P. Liebisch, A. Shimoni, A. Nagler, J. A. Perez-Simon, J. F. San Miguel, M. Kiehl, A. Fauser, et al.
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation
Blood,
June 1, 2004;
103(11):
4056 - 4061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kaufmann, J. Ackermann, H. Greinix, T. Nosslinger, H. Gisslinger, A. Keck, H. Ludwig, N. Worel, P. Kalhs, C. Zielinski, et al.
Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features
Ann. Onc.,
November 1, 2003;
14(11):
1667 - 1672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. V. Smadja, C. Bastard, C. Brigaudeau, D. Leroux, and C. Fruchart
Hypodiploidy is a major prognostic factor in multiple myeloma
Blood,
October 1, 2001;
98(7):
2229 - 2238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Facon, H. Avet-Loiseau, G. Guillerm, P. Moreau, F. Genevieve, M. Zandecki, J.-L. Lai, X. Leleu, J.-P. Jouet, F. Bauters, et al.
Chromosome 13 abnormalities identified by FISH analysis and serum {beta}2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
Blood,
March 15, 2001;
97(6):
1566 - 1571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Slovak, L. Tcheurekdjian, F. F. Zhang, and J. L. Murata-Collins
Simultaneous Detection of Multiple Genetic Aberrations in Single Cells by Spectral Fluorescence in Situ Hybridization
Cancer Res.,
February 1, 2001;
61(3):
831 - 836.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Shaughnessy Jr, E. Tian, J. Sawyer, K. Bumm, R. Landes, A. Badros, C. Morris, G. Tricot, J. Epstein, and B. Barlogie
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
Blood,
August 15, 2000;
96(4):
1505 - 1511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Zojer, R. Konigsberg, J. Ackermann, E. Fritz, S. Dallinger, E. Kromer, H. Kaufmann, L. Riedl, H. Gisslinger, S. Schreiber, et al.
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
Blood,
March 15, 2000;
95(6):
1925 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Konigsberg, N. Zojer, J. Ackermann, E. Kromer, H. Kittler, E. Fritz, H. Kaufmann, T. Nosslinger, L. Riedl, H. Gisslinger, et al.
Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma
J. Clin. Oncol.,
February 14, 2000;
18(4):
804 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. V. Smadja, C. Bastard, C. Brigaudeau;, R. Garcia-Sanz, A. Orfao, and J.F. S. Miguel
Primary Plasma Cell Leukemia and Multiple Myeloma: One or Two Diseases According to the Methodology
Blood,
November 15, 1999;
94(10):
3607 - 3609.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, J.-Y. Li, N. Morineau, T. Facon, C. Brigaudeau, J.-L. Harousseau, B. Grosbois, and R. Bataille
Monosomy 13 Is Associated With the Transition of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
Blood,
October 15, 1999;
94(8):
2583 - 2589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, T. Facon, A. Daviet, C. Godon, M.-J. Rapp, J.-L. Harousseau, B. Grosbois, and R. Bataille
14q32 Translocations and Monosomy 13 Observed in Monoclonal Gammopathy of Undetermined Significance Delineate a Multistep Process for the Oncogenesis of Multiple Myeloma
Cancer Res.,
September 1, 1999;
59(18):
4546 - 4550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Garcia-Sanz, A. Orfao, M. Gonzalez, M.D. Tabernero, J. Blade, M.J. Moro, J. Fernandez-Calvo, M.A. Sanz, J.A. Perez-Simon, A. Rasillo, et al.
Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics
Blood,
February 1, 1999;
93(3):
1032 - 1037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
